PARSIPPANY, N.J., Jan. 12, 2016 /PRNewswire/ — Interpace Diagnostics (NASDAQ: IDXG) announced today that Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world’s leading health care diagnostics company, will begin offering Interpace’s new ThyraMirTM microRNA classifier test. Physicians will be able to order ThyraMir through LabCorp, in addition to Interpace’s ThyGenX® oncogene panel, which LabCorp already offers. These innovative assays provide enhanced options for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
Studies show that the combination of the two molecular tests provides unprecedented high sensitivity and specificity, enabling physicians to either rule in or rule out malignancy in thyroid nodules initially deemed indeterminate by standard cytology. In addition to providing more precise diagnostic information, performing the tests together will in many cases eliminate the need for patients to undergo a second fine needle biopsy to collect the specimen typically needed for further tests.
“This agreement with LabCorp expands the reach of our molecular diagnostic tests for indeterminate thyroid nodules, and is a significant step in increasing access to the unmatched benefits of [click to continue…]
The International Journal of Endocrinology is looking for contributions in the field of miRNAs & thyroid cancer.
Both, original research articles as well as review articles that explore the influence of microRNAs in the development and progression of thyroid tumors will be considered. In addition, the editors are interested in articles that attempt to define the diagnostic and prognostic role of microRNAs in thyroid cancer. Potential topics include, but are not limited to:
- Molecular profiling of microRNAs in human thyroid tumors
- The diagnostic value of microRNAs in thyroid nodules
- Circulating microRNAs as diagnostic markers in thyroid cancer
- Expression of microRNAs in animal models of thyroid carcinogenesis
- Mechanisms of regulation of microRNAs expression in thyroid tumors
- MicroRNAs as tumor suppressors and oncogenes in thyroid cancer
- The utility of microRNAs as markers of aggressiveness and their role in metastasis of thyroid cancer
- Identification of interactions between microRNAs and target genes relevant in thyroid carcinogenesis
- SNPs in microRNAs or in 3′ untranslated region of target genes and thyroid tumor susceptibility
||Friday, 22 February 2013
|First Round of Reviews:
||Friday, 17 May 2013
||Friday, 12 July 2013
For more information please see the full post at the publisher’s page: